Shuyang Zhang

TL;DR: A 69-year-old man with Covid-19 diagnosed in January 2020 in Wuhan, China, along with two other critically ill patients with Covod-19 who were also seen in the same intensive care unit are described.

TL;DR: The clinical and immunological characteristics of severe patients, and the current evidence and share the experience in anti-inflammation treatment of patients with severe COVID-19 that may have an impaired immune system are discussed.

TL;DR: The existence of hypercoagulation status in critical COVID-2019 patients with acro-ischemia should be monitored closely, and anticoagulation therapy can be considered in selected patients.

TL;DR: The Acarbose Cardiovascular Evaluation (ACE) trial was a randomized, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China as discussed by the authors, where patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1), in blocks by site, by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular secondary prevention therapy.

TL;DR: IP-10 and MCP-1 are biomarkers associated with the severity of CO VID-19 disease and can be related to the risk of death in COVID-19 patients.